Ingress-health and Indivumed Announce an International Partnership on Real-World Evidence Studies in Oncology (FOTO)

Hamburg/Wismar/Rotterdam/Oviedo (ots) -

Ingress-health B.V. and Indivumed GmbH announced today the launch
of an exclusive partnership on real-world evidence (RWE) studies in
oncology.

According to the Robert Koch Institute in Germany (RKI), cancer is
the second most important cause of death in Germany (www.rki.de).
Understanding the real-world treatment of oncology patients as well
as identifying the most effective/safe treatments in clinical
practice is therefore of utmost importance. Still, availability of
such data ("real-world" data) in oncology is scarce, especially in
Europe and Germany. Based on the announced cooperation,
Ingress-health and Indivumed are now able to use the unique Indivumed
Liquid Biopsy RWE oncology database for future RWE research.

The database already includes more than 20,000 oncology patients,
with additional patients being added every month, and provides
information about patient and disease characteristics, treatments,
treatment-associated outcomes as well as mutation test results. The
database is built based on cases coming from German oncology clinics
but will be expanded with new countries in the coming months.

According to Prof. Dr. Wilke, partner at Ingress-health, access to
this databank fills a gap that existed so far in RWE oncology
research. "With our Ingress RWE operations, we were able to generate
epidemiological, treatment pattern and mortality data, based mainly
on claims data analyses so far. But we were always missing
disease-specific data and, increasingly important, mutation data on
oncology patients." Prof. Dr. Juhl, CEO of Indivumed, adds: "Our
mutation data in the Liquid Biopsy databank are unique. First, all
mutation test results from clinical practice are available in our
database. Second, for all patients a longitudinal plasma sample
collection is being done. This offers us the possibility to test for
any mutations in a retrospective way - a unique capability even
outside of Germany."

Ingress-health and Indivumed offer to do scientific analyses based
on the Indivumed Liquid Biopsy databank, in cooperation with all
partners interested in scientific oncology data. In these studies,
Ingress-health takes over the responsibility to plan the studies and
to conduct the statistical analyses, whereas Indivumed takes care of
maintaining and expanding the database globally.

Prof. Dr. Juhl and Prof. Dr. Wilke summarize: "The outstanding
scientific expertise and infrastructure of both Ingress-health and
Indivumed provide a unique opportunity to take the next step in
real-world oncology research. That hopefully helps to improve
treatment and outcomes of oncology patients in the future."

About Ingress-health

Ingress-health is one of the leading European health care
consultancies focusing on projects and studies around new
pharmaceutical products. It conducts projects in indirect treatment
comparisons, modelling, evidence synthesis and real-world evidence
topics, using advanced statistical methods. Within RWE,
Ingress-health conducts database studies, other observational studies
and patient surveys focusing on elicitation of patient-reported
outcomes and preferences. It has a specific emphasis on oncology
diseases. Ingress-health currently operates three offices in Wismar
(Germany), Rotterdam (Netherlands) and Oviedo (Spain). For more
information see www.ingress-health.com

About Indivumed

Indivumed a global oncology research company based in Hamburg,
Germany, has established the world's leading multi-omics cancer
database and biobank. Its proprietary processes and technology
preserve the patterns of biomolecules such as RNA, DNA, and proteins
as they existed in the human body. The cancer database contains
genomics, transcriptomics, proteomics, phospho-proteomics and
immuno-phenotype imaging information together with clinical and
outcome data, making it a unique resource for cancer research in the
post-genomics era. With leading edge data analytics capabilities, the
cancer library allows for in-depth understanding of the underlying
mechanisms of a patient's cancer, addressing important demands in
translational research and molecular diagnostics to support
implementation of personalized healthcare. For more information see
www.indivumed.com

Contact:
Media contact information Ingress-health:
Diana Cizova
Ingress-health, Communications & Corporate Development
Alter Holzhafen 19
23966 Wismar
Germany
Phone: 0049-3841.758.1010

diana.cizova@ingress-health.com

www.ingress-health.com

Media contact information Indivumed:
Corrine Gormont
VP, Live Wire Strategic Communications
2800 Shirlington Road, Suite 401
Arlington VA 22206
United States of America
Phone: 00-1-703.519.1600

cgormont@livewiredc.com

www.indivumed.com

Original-Content von: Indivumed GmbH, übermittelt durch news aktuell